12:00 AM
 | 
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lenvatinib: Phase I/II data

An open-label Japanese and Korean Phase I/II trial in 46 patients with advanced HCC and Child-Pugh A status showed that lenvatinib led to a median TTP of 7.5 months based on an independent radiologist review. Lenvatinib produced partial response in 32.6% of patients and stable disease in 45.7% of patients. Median observed OS was 13.9 months based on a minimum...

Read the full 276 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >